EC
BOLT icon

EcoR1 Capital’s Bolt Biotherapeutics BOLT Stock Holding History

EcoR1 Capital’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,500
Closed -$306K – 78
2022
Q2 		$306K Hold
7,500
– – 0.01% 79
2022
Q1 		$411K Hold
7,500
– – 0.01% 84
2021
Q4 		$735K Hold
7,500
– – 0.02% 70
2021
Q3 		$1.85M Hold
7,500
– – 0.06% 55
2021
Q2 		$2.32M Hold
7,500
– – 0.09% 51
2021
Q1 		$4.94M Buy
+7,500
New +$4.88M 0.22% 41

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

EcoR1 Capital's BOLT Position: Q3 2022 in Review

EcoR1 Capital sold out of Bolt Biotherapeutics (BOLT) in Q3 2022, closing a stake of 7,500 shares — an estimated $306K sold.

EcoR1 Capital first reported a position in BOLT in Q1 2021 and held it in 6 quarters. The position peaked at $4.94M in Q1 2021. 56 funds tracked by Wall St. Rank hold BOLT as of Q3 2022.

  • EcoR1 Capital reported no remaining Bolt Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • EcoR1 Capital sold 7,500 Bolt Biotherapeutics shares in Q3 2022, an estimated $306K.
  • EcoR1 Capital first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 6 quarters.
  • EcoR1 Capital's Bolt Biotherapeutics position peaked at $4.94M in Q1 2021.
  • 56 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2022.

Based on EcoR1 Capital's 13F filing for Q3 2022, filed 14 Nov 2022.